Woman Gets 5-Year Drug Import Ban, Ghosts Her Own Hearing
Published Date: 11/25/2025
Notice
Summary
Nicole Shelby Randall is officially banned for 5 years from importing any drugs into the U.S. because she was convicted of bringing in a bad drug that broke federal law. She didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on November 25, 2025. She can apply to end the ban anytime, but must follow special rules to keep her info private.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Five‑Year Import Ban for Nicole Randall
Nicole Shelby Randall is debarred for 5 years from importing or offering for import any drug into the United States, effective November 25, 2025. The debarment follows her January 22, 2025 felony conviction for introducing an adulterated drug into interstate commerce, and FDA states that importing drugs by, with the assistance of, or at the direction of Ms. Randall is a prohibited act.
Right to Apply and Public Filing Rules
Ms. Randall (or anyone seeking termination of debarment) may apply to end the debarment at any time under section 306(d)(1). Applications submitted electronically to https://www.regulations.gov will be posted publicly unchanged; to keep information confidential you must submit a written/paper application with two copies (one marked confidential and one redacted) to the Dockets Management Staff as described in the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2025-21074, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on December 19, 2025, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info of applicants. Researchers waiting on funding decisions should note this date, but no new costs or changes to the process are announced.
Next: 2025-21076, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 6, 2026, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info. Scientists and researchers applying for grants should note this date, but no new costs or changes affect the public.